Axogen Inc Aktie
Beste aktive Einschätzung
Deine Einschätzung
Axogen Inc Aktie
Was spricht für und gegen Axogen Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Axogen Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Axogen Inc | -0,08 % | 1,60 % | -8,98 % | 215,58 % | 27,36 % | 381,89 % | 113,53 % |
| Simulations Plus | 0,00 % | 0,64 % | 1,94 % | -57,30 % | 2,60 % | -57,30 % | -58,64 % |
| MicroVision Inc | 5,74 % | -27,12 % | -14,29 % | -79,22 % | -70,61 % | -93,55 % | -98,17 % |
| Fluidigm Corp. | -0,72 % | -12,42 % | 4,69 % | -43,22 % | -36,79 % | -68,10 % | -88,08 % |
Kommentare
Der Beitrag wird untersucht
Der Beitrag wird untersucht
News
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
DAFNA Capital Management cut its holding in Axogen (NASDAQ:AXGN) by 265,456 shares in the fourth quarter, an estimated $6.53 million trade based on quarterly average pricing, according to a February




